| Dr David Thomas Pilkinton, MD, PHD | |
|
9440 Poppy Dr, Dallas, TX 75218 | |
| (972) 587-6717 | |
| Not Available |
| Full Name | Dr David Thomas Pilkinton |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 11 Years |
| Location | 9440 Poppy Dr, Dallas, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164869525 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | Q4250 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baylor Scott And White Medical Center Lake Pointe | Rowlett, TX | Hospital |
| Baylor Scott & White Medical Center-white Rock | Dallas, TX | Hospital |
| Dallas Regional Medical Center | Mesquite, TX | Hospital |
| Hunt Regional Medical Center | Greenville, TX | Hospital |
| Mc Camey Hospital | Mccamey, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| North Star Mri Of Frisco Lp | 2769574854 | 39 |
| Singleton Associates Pa | 6305731118 | 691 |
| North Star Diagnostic Imaging, Llc | 8729118021 | 38 |
News Archive
The U.S. Food and Drug Administration today announced membership and meeting information for the Tobacco Products Scientific Advisory Committee. The Committee, required through the Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act), will provide advice, information, and recommendations to FDA on a wide range of tobacco-related issues.
Victoria's nursing and health care staff are among those most at risk of physical assault from violent patients and families and now the Victorian government has come up with new laws to protect them.
Otsuka Pharmaceutical Co., Ltd. announced today that the European Medicines Agency (EMA) has accepted the submission of a marketing authorisation application (MAA) for the potential approval of tolvaptan for the treatment of autosomal dominant polycystic kidney disease (ADPKD).
The U.S. Food and Drug Administration has warned Genetech, Inc. of San Diego, California and its president, Edwin N. Pinos for marketing stem cell products without FDA approval and for significant deviations from current good tissue practice and current good manufacturing practice requirements, including some violations that may have led to microbial contamination, potentially causing serious blood infections in patients.
While breakthrough treatments have emerged for several cancers over the last two decades, driving striking improvements in survival and other clinical outcomes, too little is known about the risk of therapy-related hematologic cancers following targeted and immunotherapeutic approaches.
› Verified 4 days ago
| Entity Name | University Of Texas Southwestern Medical Center At Dallas |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972579365 PECOS PAC ID: 0648188250 Enrollment ID: O20031106000792 |
News Archive
The U.S. Food and Drug Administration today announced membership and meeting information for the Tobacco Products Scientific Advisory Committee. The Committee, required through the Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act), will provide advice, information, and recommendations to FDA on a wide range of tobacco-related issues.
Victoria's nursing and health care staff are among those most at risk of physical assault from violent patients and families and now the Victorian government has come up with new laws to protect them.
Otsuka Pharmaceutical Co., Ltd. announced today that the European Medicines Agency (EMA) has accepted the submission of a marketing authorisation application (MAA) for the potential approval of tolvaptan for the treatment of autosomal dominant polycystic kidney disease (ADPKD).
The U.S. Food and Drug Administration has warned Genetech, Inc. of San Diego, California and its president, Edwin N. Pinos for marketing stem cell products without FDA approval and for significant deviations from current good tissue practice and current good manufacturing practice requirements, including some violations that may have led to microbial contamination, potentially causing serious blood infections in patients.
While breakthrough treatments have emerged for several cancers over the last two decades, driving striking improvements in survival and other clinical outcomes, too little is known about the risk of therapy-related hematologic cancers following targeted and immunotherapeutic approaches.
› Verified 4 days ago
| Entity Name | Singleton Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538107875 PECOS PAC ID: 6305731118 Enrollment ID: O20040315000385 |
News Archive
The U.S. Food and Drug Administration today announced membership and meeting information for the Tobacco Products Scientific Advisory Committee. The Committee, required through the Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act), will provide advice, information, and recommendations to FDA on a wide range of tobacco-related issues.
Victoria's nursing and health care staff are among those most at risk of physical assault from violent patients and families and now the Victorian government has come up with new laws to protect them.
Otsuka Pharmaceutical Co., Ltd. announced today that the European Medicines Agency (EMA) has accepted the submission of a marketing authorisation application (MAA) for the potential approval of tolvaptan for the treatment of autosomal dominant polycystic kidney disease (ADPKD).
The U.S. Food and Drug Administration has warned Genetech, Inc. of San Diego, California and its president, Edwin N. Pinos for marketing stem cell products without FDA approval and for significant deviations from current good tissue practice and current good manufacturing practice requirements, including some violations that may have led to microbial contamination, potentially causing serious blood infections in patients.
While breakthrough treatments have emerged for several cancers over the last two decades, driving striking improvements in survival and other clinical outcomes, too little is known about the risk of therapy-related hematologic cancers following targeted and immunotherapeutic approaches.
› Verified 4 days ago
| Entity Name | North Star Mri Of Frisco Lp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649356759 PECOS PAC ID: 2769574854 Enrollment ID: O20070821000328 |
News Archive
The U.S. Food and Drug Administration today announced membership and meeting information for the Tobacco Products Scientific Advisory Committee. The Committee, required through the Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act), will provide advice, information, and recommendations to FDA on a wide range of tobacco-related issues.
Victoria's nursing and health care staff are among those most at risk of physical assault from violent patients and families and now the Victorian government has come up with new laws to protect them.
Otsuka Pharmaceutical Co., Ltd. announced today that the European Medicines Agency (EMA) has accepted the submission of a marketing authorisation application (MAA) for the potential approval of tolvaptan for the treatment of autosomal dominant polycystic kidney disease (ADPKD).
The U.S. Food and Drug Administration has warned Genetech, Inc. of San Diego, California and its president, Edwin N. Pinos for marketing stem cell products without FDA approval and for significant deviations from current good tissue practice and current good manufacturing practice requirements, including some violations that may have led to microbial contamination, potentially causing serious blood infections in patients.
While breakthrough treatments have emerged for several cancers over the last two decades, driving striking improvements in survival and other clinical outcomes, too little is known about the risk of therapy-related hematologic cancers following targeted and immunotherapeutic approaches.
› Verified 4 days ago
| Entity Name | North Star Diagnostic Imaging, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467787739 PECOS PAC ID: 8729118021 Enrollment ID: O20100614000182 |
News Archive
The U.S. Food and Drug Administration today announced membership and meeting information for the Tobacco Products Scientific Advisory Committee. The Committee, required through the Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act), will provide advice, information, and recommendations to FDA on a wide range of tobacco-related issues.
Victoria's nursing and health care staff are among those most at risk of physical assault from violent patients and families and now the Victorian government has come up with new laws to protect them.
Otsuka Pharmaceutical Co., Ltd. announced today that the European Medicines Agency (EMA) has accepted the submission of a marketing authorisation application (MAA) for the potential approval of tolvaptan for the treatment of autosomal dominant polycystic kidney disease (ADPKD).
The U.S. Food and Drug Administration has warned Genetech, Inc. of San Diego, California and its president, Edwin N. Pinos for marketing stem cell products without FDA approval and for significant deviations from current good tissue practice and current good manufacturing practice requirements, including some violations that may have led to microbial contamination, potentially causing serious blood infections in patients.
While breakthrough treatments have emerged for several cancers over the last two decades, driving striking improvements in survival and other clinical outcomes, too little is known about the risk of therapy-related hematologic cancers following targeted and immunotherapeutic approaches.
› Verified 4 days ago
| Entity Name | North Star Mri Lp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033174701 PECOS PAC ID: 5890762330 Enrollment ID: O20110524000030 |
News Archive
The U.S. Food and Drug Administration today announced membership and meeting information for the Tobacco Products Scientific Advisory Committee. The Committee, required through the Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act), will provide advice, information, and recommendations to FDA on a wide range of tobacco-related issues.
Victoria's nursing and health care staff are among those most at risk of physical assault from violent patients and families and now the Victorian government has come up with new laws to protect them.
Otsuka Pharmaceutical Co., Ltd. announced today that the European Medicines Agency (EMA) has accepted the submission of a marketing authorisation application (MAA) for the potential approval of tolvaptan for the treatment of autosomal dominant polycystic kidney disease (ADPKD).
The U.S. Food and Drug Administration has warned Genetech, Inc. of San Diego, California and its president, Edwin N. Pinos for marketing stem cell products without FDA approval and for significant deviations from current good tissue practice and current good manufacturing practice requirements, including some violations that may have led to microbial contamination, potentially causing serious blood infections in patients.
While breakthrough treatments have emerged for several cancers over the last two decades, driving striking improvements in survival and other clinical outcomes, too little is known about the risk of therapy-related hematologic cancers following targeted and immunotherapeutic approaches.
› Verified 4 days ago
| Entity Name | North Star Mcd, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063712461 PECOS PAC ID: 2668659434 Enrollment ID: O20110602000702 |
News Archive
The U.S. Food and Drug Administration today announced membership and meeting information for the Tobacco Products Scientific Advisory Committee. The Committee, required through the Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act), will provide advice, information, and recommendations to FDA on a wide range of tobacco-related issues.
Victoria's nursing and health care staff are among those most at risk of physical assault from violent patients and families and now the Victorian government has come up with new laws to protect them.
Otsuka Pharmaceutical Co., Ltd. announced today that the European Medicines Agency (EMA) has accepted the submission of a marketing authorisation application (MAA) for the potential approval of tolvaptan for the treatment of autosomal dominant polycystic kidney disease (ADPKD).
The U.S. Food and Drug Administration has warned Genetech, Inc. of San Diego, California and its president, Edwin N. Pinos for marketing stem cell products without FDA approval and for significant deviations from current good tissue practice and current good manufacturing practice requirements, including some violations that may have led to microbial contamination, potentially causing serious blood infections in patients.
While breakthrough treatments have emerged for several cancers over the last two decades, driving striking improvements in survival and other clinical outcomes, too little is known about the risk of therapy-related hematologic cancers following targeted and immunotherapeutic approaches.
› Verified 4 days ago
| Entity Name | North Star Fm Lp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174812028 PECOS PAC ID: 1153591763 Enrollment ID: O20110908001884 |
News Archive
The U.S. Food and Drug Administration today announced membership and meeting information for the Tobacco Products Scientific Advisory Committee. The Committee, required through the Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act), will provide advice, information, and recommendations to FDA on a wide range of tobacco-related issues.
Victoria's nursing and health care staff are among those most at risk of physical assault from violent patients and families and now the Victorian government has come up with new laws to protect them.
Otsuka Pharmaceutical Co., Ltd. announced today that the European Medicines Agency (EMA) has accepted the submission of a marketing authorisation application (MAA) for the potential approval of tolvaptan for the treatment of autosomal dominant polycystic kidney disease (ADPKD).
The U.S. Food and Drug Administration has warned Genetech, Inc. of San Diego, California and its president, Edwin N. Pinos for marketing stem cell products without FDA approval and for significant deviations from current good tissue practice and current good manufacturing practice requirements, including some violations that may have led to microbial contamination, potentially causing serious blood infections in patients.
While breakthrough treatments have emerged for several cancers over the last two decades, driving striking improvements in survival and other clinical outcomes, too little is known about the risk of therapy-related hematologic cancers following targeted and immunotherapeutic approaches.
› Verified 4 days ago
| Entity Name | North Star Cn Lp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013305945 PECOS PAC ID: 0547589376 Enrollment ID: O20150429001555 |
News Archive
The U.S. Food and Drug Administration today announced membership and meeting information for the Tobacco Products Scientific Advisory Committee. The Committee, required through the Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act), will provide advice, information, and recommendations to FDA on a wide range of tobacco-related issues.
Victoria's nursing and health care staff are among those most at risk of physical assault from violent patients and families and now the Victorian government has come up with new laws to protect them.
Otsuka Pharmaceutical Co., Ltd. announced today that the European Medicines Agency (EMA) has accepted the submission of a marketing authorisation application (MAA) for the potential approval of tolvaptan for the treatment of autosomal dominant polycystic kidney disease (ADPKD).
The U.S. Food and Drug Administration has warned Genetech, Inc. of San Diego, California and its president, Edwin N. Pinos for marketing stem cell products without FDA approval and for significant deviations from current good tissue practice and current good manufacturing practice requirements, including some violations that may have led to microbial contamination, potentially causing serious blood infections in patients.
While breakthrough treatments have emerged for several cancers over the last two decades, driving striking improvements in survival and other clinical outcomes, too little is known about the risk of therapy-related hematologic cancers following targeted and immunotherapeutic approaches.
› Verified 4 days ago
| Entity Name | Sierra Vista Hospital 69 |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760446009 PECOS PAC ID: 0143122416 Enrollment ID: O20170718001318 |
News Archive
The U.S. Food and Drug Administration today announced membership and meeting information for the Tobacco Products Scientific Advisory Committee. The Committee, required through the Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act), will provide advice, information, and recommendations to FDA on a wide range of tobacco-related issues.
Victoria's nursing and health care staff are among those most at risk of physical assault from violent patients and families and now the Victorian government has come up with new laws to protect them.
Otsuka Pharmaceutical Co., Ltd. announced today that the European Medicines Agency (EMA) has accepted the submission of a marketing authorisation application (MAA) for the potential approval of tolvaptan for the treatment of autosomal dominant polycystic kidney disease (ADPKD).
The U.S. Food and Drug Administration has warned Genetech, Inc. of San Diego, California and its president, Edwin N. Pinos for marketing stem cell products without FDA approval and for significant deviations from current good tissue practice and current good manufacturing practice requirements, including some violations that may have led to microbial contamination, potentially causing serious blood infections in patients.
While breakthrough treatments have emerged for several cancers over the last two decades, driving striking improvements in survival and other clinical outcomes, too little is known about the risk of therapy-related hematologic cancers following targeted and immunotherapeutic approaches.
› Verified 4 days ago
| Entity Name | North Star Fp Lp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033630835 PECOS PAC ID: 6800168576 Enrollment ID: O20170816002017 |
News Archive
The U.S. Food and Drug Administration today announced membership and meeting information for the Tobacco Products Scientific Advisory Committee. The Committee, required through the Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act), will provide advice, information, and recommendations to FDA on a wide range of tobacco-related issues.
Victoria's nursing and health care staff are among those most at risk of physical assault from violent patients and families and now the Victorian government has come up with new laws to protect them.
Otsuka Pharmaceutical Co., Ltd. announced today that the European Medicines Agency (EMA) has accepted the submission of a marketing authorisation application (MAA) for the potential approval of tolvaptan for the treatment of autosomal dominant polycystic kidney disease (ADPKD).
The U.S. Food and Drug Administration has warned Genetech, Inc. of San Diego, California and its president, Edwin N. Pinos for marketing stem cell products without FDA approval and for significant deviations from current good tissue practice and current good manufacturing practice requirements, including some violations that may have led to microbial contamination, potentially causing serious blood infections in patients.
While breakthrough treatments have emerged for several cancers over the last two decades, driving striking improvements in survival and other clinical outcomes, too little is known about the risk of therapy-related hematologic cancers following targeted and immunotherapeutic approaches.
› Verified 4 days ago
| Entity Name | North Star Gv Lp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922512664 PECOS PAC ID: 0648539023 Enrollment ID: O20180110000546 |
News Archive
The U.S. Food and Drug Administration today announced membership and meeting information for the Tobacco Products Scientific Advisory Committee. The Committee, required through the Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act), will provide advice, information, and recommendations to FDA on a wide range of tobacco-related issues.
Victoria's nursing and health care staff are among those most at risk of physical assault from violent patients and families and now the Victorian government has come up with new laws to protect them.
Otsuka Pharmaceutical Co., Ltd. announced today that the European Medicines Agency (EMA) has accepted the submission of a marketing authorisation application (MAA) for the potential approval of tolvaptan for the treatment of autosomal dominant polycystic kidney disease (ADPKD).
The U.S. Food and Drug Administration has warned Genetech, Inc. of San Diego, California and its president, Edwin N. Pinos for marketing stem cell products without FDA approval and for significant deviations from current good tissue practice and current good manufacturing practice requirements, including some violations that may have led to microbial contamination, potentially causing serious blood infections in patients.
While breakthrough treatments have emerged for several cancers over the last two decades, driving striking improvements in survival and other clinical outcomes, too little is known about the risk of therapy-related hematologic cancers following targeted and immunotherapeutic approaches.
› Verified 4 days ago
| Entity Name | North Star Npt, Lp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699387647 PECOS PAC ID: 8426468265 Enrollment ID: O20201105000633 |
News Archive
The U.S. Food and Drug Administration today announced membership and meeting information for the Tobacco Products Scientific Advisory Committee. The Committee, required through the Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act), will provide advice, information, and recommendations to FDA on a wide range of tobacco-related issues.
Victoria's nursing and health care staff are among those most at risk of physical assault from violent patients and families and now the Victorian government has come up with new laws to protect them.
Otsuka Pharmaceutical Co., Ltd. announced today that the European Medicines Agency (EMA) has accepted the submission of a marketing authorisation application (MAA) for the potential approval of tolvaptan for the treatment of autosomal dominant polycystic kidney disease (ADPKD).
The U.S. Food and Drug Administration has warned Genetech, Inc. of San Diego, California and its president, Edwin N. Pinos for marketing stem cell products without FDA approval and for significant deviations from current good tissue practice and current good manufacturing practice requirements, including some violations that may have led to microbial contamination, potentially causing serious blood infections in patients.
While breakthrough treatments have emerged for several cancers over the last two decades, driving striking improvements in survival and other clinical outcomes, too little is known about the risk of therapy-related hematologic cancers following targeted and immunotherapeutic approaches.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr David Thomas Pilkinton, MD, PHD 3836 Crest Cove Cir, Dallas, TX 75244-7224 Ph: (850) 287-0488 | Dr David Thomas Pilkinton, MD, PHD 9440 Poppy Dr, Dallas, TX 75218 Ph: (972) 587-6717 |
News Archive
The U.S. Food and Drug Administration today announced membership and meeting information for the Tobacco Products Scientific Advisory Committee. The Committee, required through the Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act), will provide advice, information, and recommendations to FDA on a wide range of tobacco-related issues.
Victoria's nursing and health care staff are among those most at risk of physical assault from violent patients and families and now the Victorian government has come up with new laws to protect them.
Otsuka Pharmaceutical Co., Ltd. announced today that the European Medicines Agency (EMA) has accepted the submission of a marketing authorisation application (MAA) for the potential approval of tolvaptan for the treatment of autosomal dominant polycystic kidney disease (ADPKD).
The U.S. Food and Drug Administration has warned Genetech, Inc. of San Diego, California and its president, Edwin N. Pinos for marketing stem cell products without FDA approval and for significant deviations from current good tissue practice and current good manufacturing practice requirements, including some violations that may have led to microbial contamination, potentially causing serious blood infections in patients.
While breakthrough treatments have emerged for several cancers over the last two decades, driving striking improvements in survival and other clinical outcomes, too little is known about the risk of therapy-related hematologic cancers following targeted and immunotherapeutic approaches.
› Verified 4 days ago
Dr. Nhat-long Lam Pham, M.D., PH.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 5801 Forest Park Rd, Dallas, TX 75390 Phone: 241-645-7615 Fax: 214-645-7624 | |
Firouzeh Arjmandi, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 5323 Harry Hines Blvd., Dallas, TX 75390 Phone: 214-645-3586 | |
Dr. John Debevits Iv, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-648-3928 | |
Natalia Cabrera Almonte, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 5323 Harry Hines Blvd # E6112, Dallas, TX 75390 Phone: 214-648-2054 | |
W Crysup Sory, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 12700 Park Central Dr, Ste 430, Dallas, TX 75251 Phone: 972-239-8902 Fax: 972-661-2551 | |
Jacqueline Tyra Caire, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 5323 Harry Hines Boulevard, Dallas, TX 75390 Phone: 469-757-1000 | |
Dr. Thomas Louis Borok, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 5004 Spyglass Drive, Dallas, TX 75287 Phone: 972-931-1073 Fax: 972-931-1073 |